Erlenbach, Germany

Michael Dimantoglou

This inventor holds 1 USPTO granted patent. Top assignee: Akzo N.v.. Active years: 1989.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 1989

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Michael Dimantoglou

Introduction

Michael Dimantoglou is a notable inventor based in Erlenbach, Germany. He has made significant contributions to the field of biocompatible materials, particularly in the development of dialysis membranes. His work focuses on enhancing the biocompatibility of these membranes, which is crucial for improving patient outcomes in hemodialysis.

Latest Patents

Michael Dimantoglou holds a patent for a biocompatible cellulose dialysis membrane with increased adsorption. This innovative dialysis membrane is designed for hemodialysis and is composed of a modified cellulose structure. The unique formulation enhances biocompatibility, making it a valuable advancement in medical technology. The patent details a cellulose framework or a chitin molecule, modified to improve its properties for medical applications.

Career Highlights

Throughout his career, Dimantoglou has been associated with Akzo N.V., a leading company in the field of specialty chemicals. His work at Akzo N.V. has allowed him to collaborate with other experts in the field, including his coworker Helmut Kuhne. Together, they have focused on advancing technologies that improve healthcare solutions.

Collaborations

Due to space constraints, the details of collaborations will not be included.

Conclusion

Michael Dimantoglou's contributions to the field of biocompatible materials, particularly through his patented dialysis membrane, highlight his innovative spirit and dedication to improving healthcare technologies. His work continues to influence advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…